Skip to main content
. 2022 Aug 3;22(3):245–252. doi: 10.1007/s40268-022-00396-1

Fig. 1.

Fig. 1

Treatment response to upadacitinib in terms of Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 responses. Percentage of patients achieving EASI 50, EASI 75, EASI 90, and EASI 100 responses at the follow-up visits